Quality of life in a real-world cohort of advanced breast cancer patients

Autor: Sandra M. E. Geurts, Vivianne C. G. Tjan-Heijnen, Bram Ramaekers, M. Wouter Dercksen, Roel J.W. van Kampen, Agnes J. van de Wouw, Dorien J.A. Lobbezoo, Manuela A. Joore, Anouk K. M. Claessens, Maaike de Boer
Přispěvatelé: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: KIO Kemta (9), RS: CAPHRI - R2 - Creating Value-Based Health Care, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: MA Medische Oncologie (9)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Quality of Life Research, 29(12), 3363-3374. Springer, Cham
Quality of Life Research
ISSN: 1573-2649
0962-9343
Popis: Purpose We aimed to evaluate quality of life (QoL) using the European Quality of Life Five-Dimensions questionnaire (EQ-5D-3L) in a real-world cohort of Dutch advanced breast cancer (ABC) patients. Secondary, we reported differences in QoL between subgroups of patients based on age, comorbidity, tumor-, and treatment characteristics, and assessed the association of duration of metastatic disease and time to death with QoL. Methods ABC patients who attended the outpatient clinic between October 2010 and May 2011 were asked to fill out the EQ-5D-3L questionnaire. Patient-, disease-, and treatment characteristics were obtained from the medical files. Health-utility scores were calculated. Subgroups were described and compared for utility scores by parametric and non-parametric methods. Results A total of 92 patients were included with a median utility score of 0.691 (Interquartile range [IQR] 0.244). Patients ≥ 65 years had significantly worse median utility scores than younger patients; 0.638 versus 0.743, respectively (p = 0.017). Moreover, scores were significantly worse for patients with versus those without comorbidity (medians 0.620 versus 0.725, p = 0.005). Utility scores did not significantly differ between subgroups of tumor type, type of systemic treatment, number of previous palliative treatment(s), or number or location of metastatic site(s). The remaining survival was correlated with utility scores (correlation coefficient (r) = 0.260, p = 0.0252), especially in the subgroup r = 0.340, p = 0.0169), whereas there was no significant correlation with time since metastatic diagnosis (r = − 0.106, p = 0.3136). Conclusion Within this real-world cross-sectional study, QoL was significantly associated with age, comorbidity, and remaining survival duration. The observation of a lower QoL in ABC patients, possibly indicating the last period of life, may assist clinical decision-making on timing of cessation of systemic antitumor therapy.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje